Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil ... 7thSpace Interactive (press release) All patients receive immunosuppression with either cyclophosphamide or rituximab. The primary outcome is the time to the composite of all-cause mortality and end-stage renal disease.PEXIVAS is funded by the National Institute of Health Research (UK ... |
